Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer's disease mouse model: a comparative study with donepezil.

Foteini Vasilopoulou Sergio Rodriguez-ArevaloAndrea BagánCarmen Escolano Christian Griñán-Ferré Mercé Pallàs

Published in: British journal of pharmacology (2021)

Chronic low-dose treatment with selective I2 - ligands can be an effective treatment for AD and provide insights into combination treatments for symptomatic and disease-modifying drugs.

Keyphrases

low dose
mouse model
replacement therapy